MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Summary

This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2009-03

Primary completion

2013-09

Completion

2013-09

Drugs

Indications